Vutrisiran, a new drug made by Alnylam Pharmaceuticals to treat ATTR amyloidosis with cardiomyopathy, reduced the risk of death by 36% in patients, the drugmaker announced June 24.
The Latest
The healthcare field is facing a deluge of potential artificial intelligence products, and Durham, N.C.-based Duke Health has opened an AI testing lab to determine which products are the most effective for heart care.
Aurora, Colo.-based Rocky Mountain Regional VA Medical Center paused heart surgeries between 2022 and 2023 due to lack of staff, but did not tell the federal Veterans Health Administration, The Denver Post reported June 24.
Charlotte, N.C.-based Atrium Health Sanger Heart & Vascular Institute has become the first in the world to implant a new Duo venous stent system.
Stanford (Calif.) University researchers found chronic hypertension in pregnant patients doubled in the last two decades, from 1.8% to 3.7%.
A Seattle-based UW Medicine heart failure program is keeping patients out of the hospital and providing indefinite care for vulnerable heart failure patients.
Patients with heart failure, or suspected of having it, are not being diagnosed quickly enough, according to a study involving 8,000 patients, which was presented June 15 at the Heart Failure Association of the European Society of Cardiology.
With the exception of open heart surgery, Utica, N.Y.-based Wynn Hospital will resume all cardiac procedures June 20.
Akira Endo, PhD, a Japanese biochemist whose research helped create statins, died June 5 at 90, The New York Times reported June 12.
Akira Endo, PhD, a Japanese biochemist whose research helped create statins, died June 5 at 90, The New York Times reported June 12.